Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 perioperative nivolumab plus chemotherapy versus placebo plus chemotherapy in resectable stage II-IIIB non-small cell lung cancer
CTR20201173Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Aug 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20201173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201173.